Friess Associates’s Harvard Bioscience HBIO Stock Holding History

Friess Associates’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-18,307	Closed	-$789K	–	128
2019 Q1	$789K	Buy	+18,307	New	+$664K	0.06%	115
2015 Q2	–	Sell	-9,000	Closed	-$524K	–	158
2015 Q1	$524K	Hold	9,000	–	–	0.04%	106
2014 Q4	$510K	Buy	+9,000	New	+$429K	0.04%	99

Other funds holding HBIO

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Friess Associates's HBIO Position: Q2 2019 in Review

Friess Associates sold out of Harvard Bioscience (HBIO) in Q2 2019, closing a stake of 18,307 shares — an estimated $789K sold.

Friess Associates first reported a position in HBIO in Q4 2014 and held it in 3 quarters. The position peaked at $789K in Q1 2019. 78 funds tracked by Wall St. Rank hold HBIO as of Q2 2019.

Friess Associates reported no remaining Harvard Bioscience position as of Q2 2019 after selling out during the quarter.
Friess Associates sold 18,307 Harvard Bioscience shares in Q2 2019, an estimated $789K.
Friess Associates first reported a position in Harvard Bioscience in Q4 2014 and held it in 3 quarters.
Friess Associates's Harvard Bioscience position peaked at $789K in Q1 2019.
78 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2019.

Based on Friess Associates's 13F filing for Q2 2019, filed 14 Aug 2019.